Allosteric CB1 ligands reduced eye pain and inflammation in a mouse corneal injury model
Novel compounds that modulate CB1 receptors through an allosteric site reduced pain responses and inflammation in mice with corneal injuries.
Quick Facts
What This Study Found
The CB1 allosteric ligand GAT228 reduced pain on its own, while GAT229 and GAT211 reduced pain when combined with a low dose of THC. Both GAT228 alone and GAT229 with THC also reduced corneal inflammation. Effects were blocked by a CB1 antagonist but persisted in CB2 knockout mice.
Key Numbers
GAT228 at 2% concentration reduced pain scores. Combination of 0.5% GAT229 with 0.4% delta-8-THC significantly reduced pain. The 0.4% THC dose alone was subthreshold (inactive).
How They Did This
Corneal hyperalgesia was induced by chemical cauterization in wildtype and CB2 knockout mice. Pain was assessed after capsaicin stimulation at 6 hours post-injury. Novel allosteric CB1 ligands were tested alone and in combination with delta-8-THC.
Why This Research Matters
Current eye pain treatments have significant limitations. Allosteric modulators could enhance the therapeutic effects of cannabinoids at lower doses while potentially reducing side effects associated with direct CB1 activation.
The Bigger Picture
Allosteric modulators represent a newer approach to cannabinoid pharmacology. By fine-tuning receptor activity rather than fully activating it, these compounds may offer therapeutic benefits with fewer unwanted effects.
What This Study Doesn't Tell Us
Animal study using a mouse model of corneal injury. Pain assessment relied on behavioral scoring. No human data on safety, tolerability, or efficacy of these compounds.
Questions This Raises
- ?Would these allosteric ligands be safe and effective in human eyes?
- ?Could this approach work for other types of ocular conditions?
- ?What is the optimal ratio of allosteric modulator to THC for pain relief?
Trust & Context
- Key Stat:
- Allosteric ligands enabled pain relief at subthreshold THC doses
- Evidence Grade:
- Preclinical animal study demonstrating proof of concept. No human data available.
- Study Age:
- 2020 animal study. Early-stage research into allosteric CB1 modulation for ocular pain.
- Original Title:
- Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation.
- Published In:
- Molecules (Basel, Switzerland), 25(2) (2020)
- Authors:
- Thapa, Dinesh(5), Cairns, Elizabeth A(2), Szczesniak, Anna-Maria, Kulkarni, Pushkar M, Straiker, Alex J, Thakur, Ganesh A, Kelly, Melanie E M
- Database ID:
- RTHC-02877
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is an allosteric ligand?
An allosteric ligand binds to a different site on a receptor than the primary (orthosteric) binding site. It can modulate the receptor's response to other compounds without directly activating or blocking it in the same way.
Why combine allosteric modulators with THC?
The allosteric modulators enhanced THC's effects, allowing pain relief at doses of THC that were too low to work on their own. This could mean therapeutic benefits with fewer side effects.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02877APA
Thapa, Dinesh; Cairns, Elizabeth A; Szczesniak, Anna-Maria; Kulkarni, Pushkar M; Straiker, Alex J; Thakur, Ganesh A; Kelly, Melanie E M. (2020). Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation.. Molecules (Basel, Switzerland), 25(2). https://doi.org/10.3390/molecules25020417
MLA
Thapa, Dinesh, et al. "Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation.." Molecules (Basel, 2020. https://doi.org/10.3390/molecules25020417
RethinkTHC
RethinkTHC Research Database. "Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocula..." RTHC-02877. Retrieved from https://rethinkthc.com/research/thapa-2020-allosteric-cannabinoid-receptor-1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.